Impotence News and Research

RSS

Erectile dysfunction, sometimes called "impotence," is the repeated inability to get or keep an erection firm enough for sexual intercourse. The word "impotence" may also be used to describe other problems that interfere with sexual intercourse and reproduction, such as lack of sexual desire and problems with ejaculation or orgasm. Using the term erectile dysfunction makes it clear that those other problems are not involved.

Many men with metastatic prostate cancer live longer on continuous hormone therapy

Many men with metastatic, hormone-sensitive prostate cancer live longer on continuous androgen-deprivation therapy (also known as hormone therapy) than on intermittent therapy, according to a seventeen-year study led by SWOG, a cancer research cooperative group funded by the National Cancer Institute (NCI).

4 Jun 2012

Doctors disagree on new prostate cancer screening guidelines

One doctor suggests the problem is the rush to treatment, not the screening; another suggests that a failure to screen men could be more costly in the long run.

25 May 2012

PSA test benefits are questionable, yet physicians struggle to stop them

Recent recommendations from the U.S. Preventive Services Task Force (USPSTF) advising elimination of routine prostate-specific antigen (PSA) screening for prostate cancer in healthy men are likely to encounter serious pushback from primary care physicians, according to results of a survey by Johns Hopkins investigators.

24 May 2012

Federal task force recommends dropping routine prostate cancer test

The U.S. Preventive Services Task Force finds scant evidence that the PSA blood test saves lives and instead says unneeded treatment leads to serious problems, including impotence and incontinence.

23 May 2012

TJU researchers to investigate Cu-64 imaging agent for prostate cancer

Jefferson's Kimmel Cancer Center and the Department of Radiology at Thomas Jefferson University received a five-year, $2.6 million grant from the National Institutes of Health (NIH) to investigate a potentially revolutionary method that can stage prostate cancers and detect recurrent disease so accurately, it would significantly reduce the number of confirmation biopsies. Such biopsies can be invasive, costly, and often lead to false-positive readings.

17 May 2012

Sunovion announces results from LATUDA open-label study for schizophrenia

Sunovion Pharmaceuticals Inc. today announced results from an open-label study that switched clinically stable, but symptomatic adult outpatients with schizophrenia from other antipsychotic agents to LATUDA.

10 May 2012

Positive results from Dainippon Sumitomo Pharma's LATUDA trials for bipolar I depression

Dainippon Sumitomo Pharma Co., Ltd. announced today results from two Phase 3 clinical trials designed to evaluate the efficacy and safety of LATUDA as adjunctive therapy and monotherapy, respectively, in patients with bipolar I depression (PREVAIL 1 and PREVAIL 2; PRogram to EValuate the Antidepressant Impact of Lurasidone).

7 May 2012

Prostate cancer diagnosis on the rise among U.K. men

Latest figures from Cancer Research UK reveal that the number of men diagnosed with prostate cancer in the UK has risen above 40,000.

4 May 2012

High intensity focused ultrasound to treat prostate cancer shows initial success

A new tumor treatment that involves heating it with highly focused ultrasound, may mean men with prostate tumors can be treated without an overnight stay in hospital and avoiding the distressing side effects associated with current therapies.

17 Apr 2012

New embolization procedure may bring hope to men with enlarged prostate

A new interventional radiology treatment, prostatic artery embolization, may bring hope to men with debilitating symptoms caused by an enlarged prostate, say the group of researchers who pioneered its use.

26 Mar 2012

Prostate cancer screening debate continues

Routine tests that help detect prostate cancer actually do reduce the risk of death from the disease, researchers said. Screening is done with a simple blood test that measures levels of prostate-specific antigen, or PSA.

15 Mar 2012

Counterfeit drugs on the Internet find their way into legitimate pharmacies

Criminal gangs are increasingly using the internet to market life-threatening counterfeit medicines and some have even turned up in legitimate outlets such as pharmacies, according to a review led by Dr Graham Jackson, editor of IJCP, the International Journal of Clinical Practice, and published in the March edition.

22 Feb 2012

Viewpoints: Contraception conscience vs. political objections; Is the mandate the 'non-tax' tax?

The president's new birth control plan would insure coverage of women's birth control without copayments or deductibles. Sounds fair, especially given that men's anti-impotence Viagra treatments have been covered by insurance plans for years.

17 Feb 2012

Combination of photodynamic therapy and software can treat internal tumours

Laser light in combination with certain drugs - known as photodynamic therapy - can destroy cancer tumours, but is today used mostly to cure skin cancer. The reason that internal tumours are not treated with the method is that the technology does not exist to check that the precise amount of light is administered. However, software developed by researchers in atomic physics at Lund University in Sweden looks like being able to solve the problem.

16 Feb 2012

Preoperative MRI may help manage neurovascular bundles during RALP

Preoperative MRI helps surgeons make more informed decisions about nerve-sparing procedures in men with prostate cancer, according to a new study published online in the journal Radiology.

25 Jan 2012

Dutaseride may help prevent progression of early stage prostate cancer: Study

A new study suggests that men with early stage prostate cancer may benefit with drugs that can slow or stop the cancer’s progress. Less than 10 percent of the 100,000 men each year who are diagnosed with early-stage prostate cancer and have the option of leaving the cancer in place. Rest get it removed using surgery or radiation. But those treatments can have serious side effects like impotence and incontinence.

24 Jan 2012

Dutasteride delays prostate cancer progression in men

For men diagnosed with low-risk, localized prostate cancer, being treated with the drug dutasteride delays disease progression and initiating active treatment, and also reduces anxiety, show the results of a three-year international clinical trial led by Dr. Neil Fleshner, Head of the Division of Urology, University Health Network.

24 Jan 2012

Annual screening tests do not decrease deaths from prostate cancer

There's new evidence that annual prostate cancer screening does not reduce deaths from the disease, even among men in their 50s and 60s and those with underlying health conditions, according to new research led by Washington University School of Medicine in St. Louis.

6 Jan 2012

FDA approves Medtronic's iPro2 Professional continuous glucose monitoring system

Medtronic, Inc. today announced the Food and Drug Administration (FDA) approval of iPro2, a next generation Professional continuous glucose monitoring (CGM) system and the latest in a series of recent diabetes technology approvals and innovations from the company.

From Medtronic 22 Nov 2011

Scientists discover how to starve prostate cancer cells

Each year about 3300 Australian men die of prostate cancer. It's Australia's second worst cancer killer for men, matching the impact of breast cancer on women. Current therapies for prostate cancer include surgical removal of the prostate, radiation, freezing the tumour or cutting off the supply of the hormone testosterone-but there are often side-effects including incontinence and impotence.

3 Nov 2011